早期慢性淋巴细胞白血病患者：基于分子谱的新风险分层。
Patients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profiling.
机构信息
Clinic for Hematology, Clinical Center of Serbia, Belgrade, Serbia.
出版信息
Leuk Lymphoma. 2011 Jul;52(7):1394-7. doi: 10.3109/10428194.2011.578311.
We investigated molecular and biological parameters reflecting the biology of chronic lymphocytic leukemia (CLL) that may help us to predict the time to first treatment (TTT). A group of 33 patients with newly diagnosed CLL (Binet stage A) were analyzed. We developed a new scoring system based on the serum levels of β(2)-microglobulin (β(2)M) and vascular endothelial growth factor (VEGF) and the expression of lipoprotein lipase (LPL). Patients with a score of 0 had a TTT of 58.4 months, while patients with a score of 3 (increased levels of β(2)M, LPL, and VEGF) had a significantly shorter TTT of only 10.6 months (p < 0.0001).
我们研究了反映慢性淋巴细胞白血病（CLL）生物学特征的分子和生物学参数，这些参数可能有助于我们预测首次治疗的时间（TTT）。对 33 例新诊断的 CLL（Binet 分期 A）患者进行了分析。我们基于β(2)-微球蛋白（β(2)M）和血管内皮生长因子（VEGF）的血清水平以及脂蛋白脂肪酶（LPL）的表达，建立了一种新的评分系统。评分 0 的患者 TTT 为 58.4 个月，而评分 3（β(2)M、LPL 和 VEGF 水平升高）的患者 TTT 显著缩短至仅 10.6 个月（p<0.0001）。
Zotero 插件